A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma
NCT ID: NCT02014142
Last Updated: 2017-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
86 participants
INTERVENTIONAL
2013-12-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
NCT01481051
A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma
NCT00855517
A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
NCT01481077
Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00650702
A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma
NCT00820300
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A. L-PPDS single occlusion
Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
Latanoprost Punctal Plug Delivery System (L-PPDS)
Latanoprost Punctal Plug Delivery System (L-PPDS)
Group B. L-PPDS double occlusion
Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
Latanoprost Punctal Plug Delivery System (L-PPDS)
Latanoprost Punctal Plug Delivery System (L-PPDS)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Latanoprost Punctal Plug Delivery System (L-PPDS)
Latanoprost Punctal Plug Delivery System (L-PPDS)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject diagnosed with bilateral OAG or OH
3. Subject IOP is currently controlled (\< 21 mmHg) with a topical prostaglandin or in conjunction with one other topical ocular hypotensive drug, not including any fixed-combination formulations (i.e., Cosopt, Combigan, Azarga, etc.) for at least one month or more
4. Subject who has lower and upper puncta \> 0.5 mm and \< 0.9 mm (pre-dilation) in both eyes
5. Subject must be able and willing to read, comprehend and give Authorization for Use/Disclosure of Health Information (HIPAA) and informed consent
6. Subject must be willing to comply with study instructions, dosing (if applicable), agree to make all office appointments, and complete the entire course of the study
7. Women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at screening and must be practicing an adequate method of birth control, including intrauterine device (IUD); oral, dermal ("patch"), implant or injected contraceptives; tubal ligation; or barrier methods with spermicide
8. Subject has a central corneal thickness of \> 500 μm and \< 600 μm in study eye
9. Subject has a BCVA or pinhole visual acuity (Snellen) of 20/100 or better in both eyes
Exclusion Criteria
2. Subject with angle-closure glaucoma, neovascular glaucoma, traumatic glaucoma or iridocorneal endothelium syndrome in either eye
3. Subject with a known sensitivity to latanoprost, timolol, fluorescein, topical anesthetic, silicone, any inactive ingredient of the L-PPDS or any other products required for the study procedures
4. Subject with a history of intolerance to topical beta-blocker therapy
5. Subject with \> 0.8 vertical cup or completely notched optic nerve head rim in either eye
6. Subject with any functionally significant visual field loss or progressive field loss within the last year in either eye
7. Subject with a history of complications, AEs, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in study eye
8. Subject with structural lid abnormalities (i.e., ectropion, entropion) in study eye
9. Subject with an active lid disease in either eye (i.e., moderate or severe blepharitis, meibomianitis) that requires medical treatment
10. Subject with a history of chronic/recurrent inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye
11. Subject who would require the use of any ocular topical medication(s), an over-the counter drop(s), ointment(s) or gel(s), other than the study ocular hypotensive medication(s) in either eye during the study period
12. Subject who has had any ophthalmic surgical procedures (i.e., glaucoma laser, minimally invasive glaucoma surgery, cataract, refractive, etc.) in study eye within the last six months or will require ophthalmic surgery before completing the study
13. Subject with a history of penetrating keratoplasty in study eye
14. Subject who is incapable of instilling ocular drops into his or her eyes
15. Subject requiring the use of a contact lens in either eye at any time during the study period
16. Subject with advanced diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion in either eye
17. Subject with a history of macular edema in either eye
18. Subject currently on any systemic medication \[i.e., beta-blocker, carbonic anhydrase inhibitors, corticosteroids (including dermal), etc.\], that may have an effect on the subject's IOP, or who will require its use during the study period (Note: an inhaled steroid, systemic beta-blocker or β-adrenoceptor antagonist may be permitted, providing the subject has maintained a stable dosage regimen for at least the last three months)
19. Subject contraindicated to therapy with a beta-blocker (i.e., history or presence of bradycardia, untreated congestive heart failure, untreated second- or third-degree heart block, sino-atrial block, myasthenia gravis, cardiogenic shock, history or presence of bronchial asthma, bronchial hyperreactivity, severe chronic obstructive pulmonary disease, or history of bronchospasm)
20. Subject with an uncontrolled systemic disease or a medical condition that may increase the risk associated with study participation or administration of study treatment or that may interfere with the interpretation of study results (e.g., autoimmune disease if the subject is on chronic medications and has ocular involvement; host-versus-graft disease)
21. Subject currently participating or has participated within the last 30 days prior to the start of this study in a drug, device or other investigational research study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mati Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Eye Center
Chandler, Arizona, United States
Arizona Glaucoma Specialists
Phoenix, Arizona, United States
Wolstan & Goldberg Eye Associates
Torrance, California, United States
Argus Research at Cape Coral Eye Center
Cape Coral, Florida, United States
Eye Associates of Fort Myers
Fort Myers, Florida, United States
Indiana Universtiy - Eugene and Marilyn Glick Eye Institute Ophthalmology Center
Indianapolis, Indiana, United States
Cincinnati Eye Institute
Edgewood, Kentucky, United States
Great Lakes Eye Care
Saint Joseph, Michigan, United States
Chu Vision Institute
Bloomington, Minnesota, United States
Ophthalmology Associates
St Louis, Missouri, United States
Comprehensive Eye Care, Ltd.
Washington, Missouri, United States
Abrams Eye Institute
Las Vegas, Nevada, United States
Ophthalmic Consultants of Long Island
Lynbrook, New York, United States
Dr. Steven T. Simmons
Slingerlands, New York, United States
Philadelphia Eye Associates
Philadelphia, Pennsylvania, United States
Wills Eye Hospital
Phildelphia, Pennsylvania, United States
University Eye Surgeons
Maryville, Tennessee, United States
Total Eye Care
Memphis, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PPL GLAU M1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.